#United States #Class Action #Radnor #investors #BioAge Labs

Reminder for BioAge Labs, Inc. Investors

Kessler Topaz Meltzer & Check, LLP, a law firm renowned for its class action lawsuits, is reaching out to investors as the deadline approaches for filing claims related to BioAge Labs, Inc. (NASDAQ: BIOA). The firm has filed a securities class action lawsuit, which has implications for those who purchased shares during BioAge’s initial public offering (IPO) on approximately September 26, 2024. Investors who experienced financial losses are particularly encouraged to review the details, as the deadline for becoming a lead plaintiff is set for March 10, 2025.

Background on the Case

The legal action against BioAge stems from allegations that the company made misleading statements regarding its business practices and clinical trials. Specifically, the suit claims that the information provided in the registration statement and prospectus for the IPO failed to appropriately disclose crucial details regarding the STRIDES Phase 2 trial for the company’s drug candidate, azelaprag. This alleged omission is poised to have misled investors about the potential safety issues observed in previous trials.

The complaint cites three key areas of concern:
1. Liver Transaminitis Risks: The claims suggest that BioAge did not appropriately disclose potential liver transaminitis risks based on findings from its past clinical STRIDES Phase 1 trials and preclinical toxicity studies.
2. Safety Assumptions: The company reportedly communicated confidence regarding the safety and primary endpoint expectations of the STRIDES trial without adequately backing those statements with thorough disclosures.
3. Misrepresentation of Operations: Due to these omissions, it is alleged that the public statements regarding BioAge's operations, business prospects, and overall market position were materially misleading.

The Process for Investors

Interested investors who believe they qualify for the claims are encouraged to contact Kessler Topaz Meltzer & Check, LLP. By doing so, they can explore the option to become a lead plaintiff representative during the litigation process. The lead plaintiff, typically representing the largest financial interest in the case, is tasked with guiding the lawsuit and selecting legal counsel to represent the class of investors. However, it is essential to note that individuals who choose not to engage will still be classified as absent class members and can benefit from any potential recoveries regardless of their participation status.

How to Make a Claim

For BioAge investors who wish to pursue this matter or seek additional information, they can reach out directly to Kessler Topaz Meltzer & Check, LLP. Legal counsel Jonathan Naji can be contacted via phone or email provided in the firm's communication, or by visiting their dedicated case link. This initiative underscores the firm’s commitment to protecting investors' rights in the face of corporate misconduct.

About Kessler Topaz Meltzer & Check, LLP

With a formidable reputation in the legal field, Kessler Topaz Meltzer & Check, LLP has made significant strides in successfully recovering damages for individuals harmed by corporate fraud and negligence. They maintain a presence in both state and federal courts across various jurisdictions, providing dedicated support to investors and consumers alike. For a comprehensive understanding of their services, interested parties are encouraged to visit their official website.

Conclusion

As the deadline approaches, it is crucial for BioAge investors to stay informed and take appropriate action. Whether you decide to engage as a lead plaintiff or simply wish to remain informed on this case, your involvement can play a vital role in addressing the concerns raised against BioAge Labs, Inc.